Clinical Trials Browser

XL647 × Clear all

NCT00086528 2022-05-13

Safety and Pharmacokinetics of XL647 Administered Orally to Subjects With Solid Tumors

Phase 1 Completed

Neoplasms

NCT00336765 2022-05-13

Study of XL647 Administered Orally Daily to Patients With Solid Tumors

Phase 1 Completed

Neoplasms

NCT00364780 2022-05-13

Study of XL647 in Subjects With Non-Small-Cell Lung Cancer

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT00522145 2022-05-13

Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or Erlotinib

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT01487174 2022-05-13

KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- or Second-Line Chemotherapy

Phase 3 Terminated

Carcinoma, Non-Small-Cell Lung

NCT02154529 2022-04-27

Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer

Phase 1/2 Terminated

17 enrolled 19 charts

Brain Neoplasms

NCT02616393 2022-03-16

Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases

Phase 2 Completed

36 enrolled 22 charts

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT02844439 2021-09-22

Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma

Phase 2 Completed

40 enrolled 25 charts

Brain Neoplasms, Glioblastoma

NCT00704392 2015-08-20

Safety Study of XL647 and XL147 Administered in Combination Daily in Adults With Solid Tumors

Phase 1 Withdrawn

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Neoplasms